CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 400 enrolled
Drug / intervention
Regenexx SD® procedurebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02848027
NCT02848027Phase 3Completed
CompareCT.gov

Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment

Regenexx, LLC·interventional·Posted Jul 28, 2016·Updated Jul 8, 2022

In Brief

A Phase 3 clinical trial evaluating Regenexx SD® procedure for Osteoarthritis, Knee. Completed, enrolled 400 participants.

Detailed Summary

Single-center, lab blinded to include up to 400 subjects with knee osteoarthritis. Collection of synovial fluid from diseased knee before and after Regenexx®SD treatment will serve as the experimental condition, i.e. the osteoarthritic knee.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis, Knee
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 28, 2016
Enrollment StartSep 8, 2015
Primary CompletionJun 30, 2020
Study CompletionAug 19, 2021
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 9.9 years ago

Interventions

Regenexx SD® procedurebiological

Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.